Please provide your email address to receive an email when new articles are posted on . Men, along with clinicians with more than 4 years’ experience, were more likely than women and less experienced ...

The potential of biologic agents to influence malignant processes has revolutionized cancer therapy. The biologic therapy causes modulation of immune responses ...

Biologic response modifiers presently approved in the USA for use in various rheumatic inflammatory diseases include three TNF inhibitors (etanercept, infliximab and adalimumab), a B-cell-directed ...

Biologic response modifiers (BRMs) represent a newer subclass of DMARDs and have proven effective in achieving remission, even for patients for whom other therapies have failed. In comparison with ...

Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and ...

Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...